In vitro and in vivo studies of adenovirus-mediated human norepinephrine transporter gene transduction to hepatocellular carcinoma

Cancer Gene Therapy

Volumn 18, Issue 3, 2011, Pages 196-205

  Jia, Z Y ^a   Deng, H F ^a   Huang, R ^a   Yang, Y Y ^b   Yang, X C ^a   Qi, Z Z ^a   Ou, X H ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

adenovirus vector; hepatocellular carcinoma; human norepinephrine transporter; radionuclide therapy; reporter gene

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 125; (3 IODOBENZYL)GUANIDINE I 131; ADENOVIRUS VECTOR; MAPROTILINE; NORADRENALIN TRANSPORTER;

ADENOVIRUS; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG INHIBITION; DRUG UPTAKE; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER SCINTISCANNING; MALE; MEDIATOR; MOUSE; NEURAL CREST; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

3-IODOBENZYLGUANIDINE; ADENOVIRIDAE; ADRENAL GLAND NEOPLASMS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEK293 CELLS; HEP G2 CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; RADIONUCLIDE IMAGING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE;

EID: 79951721766     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.70     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroentero-logy 2007; 132: 2557-2576. (Pubitemid 46890874)
3. Sherman M. Recurrence of hepatocellular carcinoma. N Engl J Med 2008; 359: 2045-2047.
4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917. (Pubitemid 37518510)
5. Omata M, Yoshida H, Shiratori Y. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin Gastroenterol Hepatol 2005; 3: S141-S143. (Pubitemid 41427747)
6. Garaventa A, Bellagamba O, Lo Piccolo MS, Milanaccio C, Lanino E, Bertolazzi L et al. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients. Br J Cancer 1999; 81: 1378-1384.
7. Sisson JC. Radiopharmaceutical treatment of pheochromo-cytomas. Ann NY Acad Sci 2002; 970: 54-60.
8. Kang TI, Brophy P, Hickeson M, Heyman S, Evans AE, Charron M et al. Targeted radiotherapy with submyeloa-blative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma. J Pediatr Hematol Oncol 2003; 25: 769-773. (Pubitemid 37238765)
9. Rose B, Matthay KK, Price D, Huberty J, Klencke B, Norton JA et al. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 2003; 98: 239-248. (Pubitemid 36828446)
10. Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ et al. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann NY Acad Sci 2006; 1073: 465-490.
11. Pacholczyk T, Blakely RD, Amara SG. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 1991; 350: 350-354. (Pubitemid 21912229)
12. +/CP-dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors, and signaling systems. Pharmacol Ther 2001; 92: 21-55. (Pubitemid 34032021)
13. Porzgen P, Bonisch H, Bruss M. Molecular cloning and organization of the coding region of the human norepinephrine transporter gene. Biochem Biophys Res Commun 1995; 215: 1145-1150.
14. Boyd M, Cunningham SH, Brown MM, Mairs RJ, Wheldon TE. Noradrenaline transporter gene transfer for radiation cell kill by 131I meta- iodobenzylguanidine. Gene Ther 1999; 6: 1147-1152. (Pubitemid 29295221)
15. Cunningham S, Boyd M, Brown MM, Carlin S, McCluskey A, Livingstone A et al. A gene therapy approach to enhance the targeted radiotherapy of neuroblastoma. Med Pediatr Oncol 2000; 35: 708-711.
16. Altmann A, Kissel M, Zitzmann S, Kubler W, Mahmut M, Peschke P et al. Increased MIBG uptake after transfer of the human norepinephrine transporter gene in rat hepatoma. J Nucl Med 2003; 44: 973-980. (Pubitemid 39663411)
17. Anton M, Wagner B, Haubner R, Bodenstein C, Essien BE, Bonisch H et al. Use of the norepinephrine transporter as a reporter gene for non-invasive imaging of genetically modified cells. J Gene Med 2004; 6: 119-126. (Pubitemid 40228010)
18. Moroz MA, Serganova I, Zanzonico P, Ageyeva L, Beresten T, Dyomina E et al. Imaging hNET reporter gene expression with 124I-MIBG. J Nucl Med 2007; 48: 827-836. (Pubitemid 47604985)
19. Mairs RJ, Boyd M. Targeting radiotherapy to cancer by gene transfer. J Biomed Biotechnol 2003; 2003: 102-109. (Pubitemid 36828264)
20. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514. (Pubitemid 28145972)
21. Antolovic D, Koch M, Bohlmann I, Kienle P, Buchler M, Weitz J. Short description of an alternative simplified method for screening recombinant clones within the 'AdEasy-System' by duplex-PCR. BMC Biotechnol 2005; 5: 1.
22. Barzon L, Stefani AL, Pacenti M, Palu G. Versatility of gene therapy vectors through viruses. Expert Opin Biol Ther 2005; 5: 639-662. (Pubitemid 40780548)
23. Jia ZY, Ou XH, Wei HY, Deng HF, Huang R, Wang JR et al. Construction and expression of replication-deficient recombi-nant adenovirus vector with hNET gene by adeasy-1 system. Sichuan Da Xue Xue Bao Yi Xue Ban 2008; 39: 523-526.
24. Vaidyanathan G, Zalutsky MR. No-carrier-added meta-[123I] iodobenzylguanidine: synthesis and preliminary evaluation. Nucl Med Biol 1995; 22: 61-64.
25. Apparsundaram S, Galli A, DeFelice LJ, Hartzell HC, Blakely RD. Acute regulation of norepinephrine transport: I. protein kinase C-linked muscarinic receptors influence transport capacity and transporter density in SK-N-SH cells. J Pharmacol Exp Ther 1998; 287: 733-743. (Pubitemid 29133677)
26. Pillai MR, Samuel G, Banerjee S, Mathew B, Sarma HD, Jurisson S. Technetium-99m complexes of polydentate amine-pyrrole and amine-thiophene ligands. Nucl Med Biol 1999; 26: 69-77. (Pubitemid 29030524)
27. Douglas JT. Adenoviral vectors for gene therapy. Mol Biotechnol 2007; 36: 71-80. (Pubitemid 350133603)
28. Ferreira TB, Alves PM, Aunins JG, Carrondo MJT. Use of adenoviral vectors as veterinary vaccines. Gene Ther 2005; 12: S73-S83. (Pubitemid 41541755)
29. Takahashi T, Takahashi K, Daniel TO. Methods in molecular medicine: high-efficiency and low-toxicity adenovirus-assisted endothelial transfection. In: Baker AH (ed). Vascular Disease: Molecular Biology and Gene Therapy Protocols, 1st edn, Humana Press: Totowa, 1999, pp 307-314.
30. Kiyono Y, Yamashita T, Doi H, Kuge Y, Katsura T, Inui KI et al. Is MIBG a substrate of P-glycoprotein? Eur J Nucl Med Mol Imaging 2007; 34: 448-452. (Pubitemid 46426984)
31. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323. (Pubitemid 27114163)
32. Kim M, Zinn KR, Barnett BG, Sumerel LA, Krasnykh V, Curiel DT et al. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 2002; 38: 1917-1926. (Pubitemid 35247478)
33. Maj J, Przegalinski E, Mogilnicka E. Hypotheses concerning the mechanism of action of antidepressant drugs. Rev Physiol Biochem Pharmacol 1984; 100: 1-74.
34. Strauss HW, Nunn A, Linder K. Nitroimidazoles for imaging hypoxic myocardium. J Nucl Cardiol 1995; 2: 437-445.
35. Vaidyanathan G, Welsh PC, Vitorello KC, Snyder S, Friedman HS, Zalutsky MR. A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells. Eur J Nucl Med Mol Imaging 2004; 31: 1362-1370. (Pubitemid 39361931)
36. Murashima S, Takeda K, Matsumura K, Yamakado K, Sakuma H, Kitano T et al. Increased lung uptake of iodine-123-MIBG in diabetics with sympathetic nervous dysfunction. J Nucl Med 1998; 39: 334-338. (Pubitemid 28114528)
37. Brader P, Kelly KJ, Chen N, Yu YA, Zhang Q, Zanzonico P et al. Imaging a genetically engineered oncolytic vaccinia virus (GLV-1h99) using a human nor-epinephrine transporter reporter gene. Clin Cancer Res 2009; 15: 3791-3801.
38. Chen N, Zhang Q, Yu YA, Stritzker J, Brader P, Schirbel A et al. A novel recombinant vaccinia virus expressing the human norepinephrine transporter retains oncolytic potential and facilitates deep-tissue imaging. Mol Med 2009; 15: 144-151.
39. Mairs RJ, Ross SC, McCluskey AG, Boyd M. A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo. J Nucl Med 2007; 48: 1519-1526. (Pubitemid 47397402)
40. Boyd M, Mairs RJ, Keith WN, Ross SC, Welsh P, Akabani G et al. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radio-astatine and harnessing radiation-mediated bystander effects. J Gene Med 2004; 6: 937-947. (Pubitemid 40228109)
41. Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Des 2000; 6: 1433-1455.